Abaxis (NASDAQ:ABAX) declared a quarterly dividend on Thursday, April 26th, RTT News reports. Shareholders of record on Friday, June 1st will be paid a dividend of 0.18 per share by the medical research company on Friday, June 15th. This represents a $0.72 annualized dividend and a yield of 0.99%. This is a boost from Abaxis’s previous quarterly dividend of $0.16.
NASDAQ ABAX traded up $2.14 during trading hours on Thursday, hitting $73.00. The company had a trading volume of 161,087 shares, compared to its average volume of 194,705. Abaxis has a 52 week low of $43.66 and a 52 week high of $78.53. The company has a market cap of $1,644.24, a P/E ratio of 55.80, a P/E/G ratio of 9.84 and a beta of 1.16.
Abaxis (NASDAQ:ABAX) last issued its earnings results on Thursday, January 25th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.26 by $0.05. Abaxis had a return on equity of 10.09% and a net margin of 10.51%. The business had revenue of $59.70 million during the quarter, compared to the consensus estimate of $59.37 million. During the same quarter last year, the company earned $0.30 EPS. The firm’s revenue was up 13.1% compared to the same quarter last year. equities research analysts predict that Abaxis will post 1.16 EPS for the current fiscal year.
In other Abaxis news, insider Kenneth Aron sold 1,412 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $69.59, for a total value of $98,261.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Prithipal Singh sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $74.63, for a total value of $149,260.00. Following the completion of the sale, the director now directly owns 44,000 shares in the company, valued at approximately $3,283,720. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,662 shares of company stock worth $1,804,604. Insiders own 4.30% of the company’s stock.
Abaxis Company Profile
Abaxis, Inc develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.